Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + IL-2 + CAPOX for Left-sided Colorectal Cancer with Obstruction
NCT06394791Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in colorectal cancer (CRC), sponsored by Jiangsu Provincial People's Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06394791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394791.